Drug Trial Radar · NCT05928806
Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial
Last checked: Nov 19, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
120
Planned (sponsor's estimate)
Start
Sep 25, 2023
Primary completion
Nov 10, 2026
Study completion Nov 10, 2027
Sponsor
- Lead sponsor
- Michael B. Atkins, MDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Agenus Inc.; Georgetown University
- First posted
- Jul 3, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, open label, multicenter Phase II trial to evaluate the efficacy and safety of botensilimab (a novel Fc enhanced Tree depleting anti-CTLA4) and balstilimab (a novel anti-PD1) relative to ipilimumab and nivolumab in treatment naïve patients with metastatic ccRCC. The study will plan to enroll 120 eligible patients randomized in a 2:1 fashion to Arm A and Arm B. Patients in all IMDC Risk Groups are included. This study utilizes a Simon's two stage design which is described in the protocol. Patients randomized to Arm A will receive botensilimab in combination with balstilimab. Patients randomized to Arm B will receive ipilimumab in combination with nivolumab. Study treatment on both arms will continue until toxicity, disease progression or a maximum of 96 total weeks (12 weeks induction, 84 weeks maintenance).
Conditions
- Advanced Renal Cell Carcinoma
Interventions
BotensilimabDrug
Botensilimab 75mg IV
BalstilimabDrug
Balstilimab 450mg IV
IpilimumabDrug
Ipilimumab 1mg/kg IV
NivolumabDrug
Nivolumab at induction: 3mg/kg IV Nivolumab at maintenance: 480mg IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine the objective response rate (ORR) of botensilimab + balstilimab in patients with treatment naïve metastatic ccRCC relative to the ORR of patients treated with ipilimumab + nivolumab.Time frame: 5 years
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
University of California San Diego
La Jolla, California
Yale University, Yale Cancer Center
New Haven, Connecticut
Georgetown University
Washington D.C., District of Columbia
Winship Cancer Institute of Emory University
Atlanta, Georgia
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Dana-Farber - Partners Cancer Care, Inc
Boston, Massachusetts
John Theurer Cancer Center
Hackensack, New Jersey
Cornell University
Ithaca, New York
Columbia University Irving Medical Center
New York, New York
Ohio State University Comprehensive Cancer Center
Columbus, Ohio
Penn Medicine Abramson Cancer Center
Philadelphia, Pennsylvania
University of Texas Southwestern Medical Center
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.